Research
Molecular
Genetic variation within the leptin-melanocortin pathway may predict response to endoscopic interventions and guide personalized treatment selection.
Understanding genetic factors can help tailor obesity treatments to individual patients.
StrongSupportsmedium confidence
Genetic variation, particularly within the leptin-melanocortin pathway, may predict response to endoscopic interventions and guide personalized treatment selection.
Why this rating
The claim is based on a review of emerging trends in treatment.
Source
Emerging Trends in Endoscopic Bariatric Therapies: Personalization Through Genomics and Synergistic Pharmacotherapy
Wissam Ghusn et al. · Journal of Clinical Medicine · 2025
DOI 10.3390/jcm14134681
reviewCited 4×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Endoscopic sleeve gastroplasty (ESG) has demonstrated durable weight loss, favorable safety, and superior cost-effectiveness compared to pharmacotherapy alone.Strong
- Combination strategies using endoscopic bariatric therapies (EBTs) and anti-obesity medications (AOMs) result in greater total-body weight loss than either modality alone.Strong
Related findings · Molecular
- QRISK decreased markedly after weight loss from 18.9 ± 2.2% to 11.2 ± 1.6%, p < 0.0001.Strong
- Normalization of 10-year cardiovascular risk and heart age is possible after substantial dietary weight loss and remission of T2DM.Strong
- The Low-Fat Plus diet resulted in a greater reduction in total cholesterol compared to the Low-Fat diet, with changes of -0.46 mmol/L (-17.6 mg/dL) versus -0.24 mmol/L (-9.2 mg/dL) respectively (P = 0.01).Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →